九号胡同

 找回密码
 注册
搜索
查看: 276|回复: 1

[灌水] 有利于vaccine stocks

[复制链接]
发表于 2023-1-24 10:29 AM | 显示全部楼层 |阅读模式


such as BNTX, PFE, MRNA etc
----------------------------------------------------------------

美国食品药品管理局(FDA)当地时间1月23日发布《未来新冠疫苗接种方案》,希望简化新冠疫苗的接种过程,提议每年为健康成年人注射一剂最新的新冠疫苗,这个过程看起来更加接近目前的流感疫苗。

咨询委员会定于1月26日(本周四)举行会议。该机构表示,展望未来,大多数人可能只需要注射一剂最新的新冠疫苗即可恢复保护力,无论他们之前的接种次数。

FDA还要求其外部顾问小组考虑每年为幼儿、老年人及免疫力低下的人群注射两次新冠疫苗。目前,大多数美国人需要首先接种两剂原始新冠疫苗,并在几个月后接种加强针。
 楼主| 发表于 2023-1-26 06:44 PM | 显示全部楼层
Michael Erman and Leroy Leo
Thu, January 26, 2023 at 3:09 PM PST
In this article:

PFE
-0.92%
Watchlist

Watchlist
Patternyahoo plus badge
Neutral
trade type U
(Recasts with details, recommendation, quotes from advisory meeting)

By Michael Erman and Leroy Leo

Jan 26 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of targeting the same coronavirus strain for initial COVID-19 vaccine doses and boosters going forward, but some expressed skepticism about whether all Americans need to receive the shots annually.

The agency is trying to simplify its COVID-19 vaccine policy as it considers whether to recommend Americans get an annual booster shot for the virus. But several members of the expert advisory group asked for more robust data on benefits of annual shots for younger, healthier people.

"We're in a very different place. We have a lot of population immunity," said Hayley Gans, professor of pediatrics at Stanford University Medical Center. "Now that people are immune, how long does that last?"

Vaccine makers Pfizer Inc with partner BioNTech SE and Moderna Inc introduced late last year updated versions of their COVID vaccines tailored to target Omicron variants as well as the original coronavirus. In the United States, those were used only as booster shots.

The FDA advisory group unanimously backed using those shots for the primary series for those who have yet to be vaccinated against COVID-19 as well.

The FDA said it envisioned holding a meeting later in the year to determine the composition of shots for the fall, although some vaccine makers might be able to produce updated shots more quickly.

Pfizer/BioNTech and Moderna were able to produce the currently available messenger RNA boosters in about three months last year, but Novavax Inc said on Thursday it would require six months to make a new version of its protein-based COVID-19 vaccine designed to match circulating coronavirus variants.

FDA would consider an earlier timeline for vaccines like Novavax's following the company's manufacturing assessment, Peter Marks, director of the agency's Center for Biologics Evaluation & Research, said.

Health officials in the Biden administration have suggested that annual, updated COVID-19 booster shots could provide a high level of protection against severe disease. (Reporting by Leroy Leo in Bengaluru, Michael Erman in Maplew
回复 支持 反对

使用道具 举报

您需要登录后才可以回帖 登录 | 注册

本版积分规则

小黑屋|手机版|www.hutong9.net

GMT-5, 2023-2-4 12:55 PM , Processed in 0.060207 second(s), 14 queries .

Powered by Discuz! X3.4

Copyright © 2001-2021, Tencent Cloud.

快速回复 返回顶部 返回列表